Tuning Reactivity of Platinum(II) Complexes

Tuning Reactivity of Platinum(II) Complexes Tuning Reactivity of Platinum(II) Complexes

pfeiffer.nele60
from pfeiffer.nele60 More from this publisher
29.07.2013 Views

Table of Contents-1 Chapter 1 .................................................................................................................................................................. 1 1.0 Introduction ...................................................................................................................................................... 1 1.1 Cancer disease ............................................................................................................................................. 1 1.2 Cancer Treatment ...................................................................................................................................... 1 1.2.1 Chemotherapy ......................................................................................................................................... 2 1.3 Platinum chemistry .................................................................................................................................. 2 1.3.1 Platinum-Based Anticancer Drugs ................................................................................................ 3 1.3.2 Cisplatin ...................................................................................................................................................... 4 1.3.2.1 Mechanism of Action ........................................................................................................................ 4 1.3.2.2 Cellular Uptake .................................................................................................................................... 5 1.3.2.3 Hydrolysis .............................................................................................................................................. 5 1.3.2.4 DNA adducts and Cell Response ................................................................................................. 6 1.3.2.5 Cisplatin Resistance .......................................................................................................................... 8 1.3.2.6 Competition between N– and S–Donor Nucleophiles ...................................................... 8 1.3.3 New and “Non-classical” platinum complexes ..................................................................... 10 1.3.3.1 Second generation Cisplatin Analogues ............................................................................... 10 1.3.3.2 Platinum(IV) complexes .............................................................................................................. 12 1.3.4 Terpyridine platinum(II) complexes ......................................................................................... 13 1.3.5. Multinuclear Platinum(II) complexes ...................................................................................... 14 1.3.5.1 Amino Linkers .................................................................................................................................. 15 1.3.5.2 Aromatic linkers .............................................................................................................................. 16 1.4 Kinetic Interest ........................................................................................................................................ 17 1.5 Aim and Scope of this Study .............................................................................................................. 17 References .............................................................................................................................................................. 20 List of Figures Figure 1.1: Classification of chemotherapy drugs................................................................................ 2 Figure 1.2: Chemical structures of selected platinum compounds ........................................................ 4 Figure 1.3: Intracellular hydrolysis and bio-activation of cisplatin in aqueous solution leading to binding at DNA in the cell nucleus. ........................................................................................................ 6 i

Figure 1.4: DNA-adduct formation with cisplatin leaving two amino groups coordinated on the platinum atom. The main adducts formed in the interaction cisplatin with DNA: (a) interstrand crosslink; (b) 1,2-intrastrand cross-link; (c) 1,3-intrastrand cross-link and; (d) protein-DNA cross-link. ..... 7 Figure 1.5: Schematic pathway of a platinum drug in cells showing how sulphur containing compounds are thought to act as potential drug reserving agents in platinum chemotherapy. ............... 9 Figure 1.6: DNA adducts formed by oxaliplatin 13 . ............................................................................... 11 Figure 1.7: Structure of a sterically hindered platinum(II) complex (ZD0473) that circumvents cisplatin resistance. ............................................................................................................................. 12 Figure 1.8: Selected Pt(II) metallo-intercalators: terpy = terpyridine, phen = phenanthroline, 4picoline = 4-methylpyridine, en = 1,2-diaminoethane, and HET = 2-hydroxyethanethiolato ligand. ................................................................................................................................................... 13 Figure 1.9: Selected Multinuclear platinum(II) complexes with flexible amino- and rigid azine and azoles ligands. , .............................................................................................................................. 15 Figure 1.10: Structure of extended terpy Pt(II) complexes; blue ring for isoquinoline ring and red for phenanthroline ring system. .................................................................................................. 18 ii

Figure 1.4: DNA-adduct formation with cisplatin leaving two amino groups coordinated on the<br />

platinum atom. The main adducts formed in the interaction cisplatin with DNA: (a) interstrand crosslink;<br />

(b) 1,2-intrastrand cross-link; (c) 1,3-intrastrand cross-link and; (d) protein-DNA cross-link. ..... 7<br />

Figure 1.5: Schematic pathway <strong>of</strong> a platinum drug in cells showing how sulphur containing<br />

compounds are thought to act as potential drug reserving agents in platinum chemotherapy. ............... 9<br />

Figure 1.6: DNA adducts formed by oxaliplatin 13 . ............................................................................... 11<br />

Figure 1.7: Structure <strong>of</strong> a sterically hindered platinum(<strong>II</strong>) complex (ZD0473) that circumvents<br />

cisplatin resistance. ............................................................................................................................. 12<br />

Figure 1.8: Selected Pt(<strong>II</strong>) metallo-intercalators: terpy = terpyridine, phen = phenanthroline, 4picoline<br />

= 4-methylpyridine, en = 1,2-diaminoethane, and HET = 2-hydroxyethanethiolato<br />

ligand. ................................................................................................................................................... 13<br />

Figure 1.9: Selected Multinuclear platinum(<strong>II</strong>) complexes with flexible amino- and rigid azine<br />

and azoles ligands. , .............................................................................................................................. 15<br />

Figure 1.10: Structure <strong>of</strong> extended terpy Pt(<strong>II</strong>) complexes; blue ring for isoquinoline ring and<br />

red for phenanthroline ring system. .................................................................................................. 18<br />

ii

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!